IQVIA (IQV) and argenx Partner to Advance Autoimmune Care
Building upon their existing collaboration, IQVIA Holdings Inc. IQV and argenx are further enhancing treatments for individuals with rare autoimmune disorders. This extended partnership aims to accelerate the expansion of clinical development and commercialization of new indications. Through innovative and integrated technology-enabled pharmacovigilance safety services, the collaboration seeks to provide groundbreaking solutions for patients.
IQV has failed to impress the shareholders in the year-to-date period despite consecutive estimate beats in the past four quarters as the company’s shares have declined 4.1% in the year-to-date period compared with its industry 10.4% fall in the same time frame.
Deal Details
While the terms of the deal have not yet been disclosed, the partnership encompasses collaborative research and development efforts to implement advanced pharmacovigilance (PV) technologies tailored to argenx's specific needs, enhances safety monitoring and adverse event reporting to ensure the patient’s well-being, and enables the efficient integration of safety data for improved decision-making and compliance.
This collaboration supports argenxs growth by providing scalable pharmacovigilance solutions, which adapt to its expanding operations, potentially expand market access and accelerate the development and commercialization of innovative treatments for rare autoimmune diseases, all while emphasizing patient safety and regulatory compliance.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
IQVIA’s Platter
The collaboration with the biotechnology leader argenx presents an opportunity for IQVIA to expand its client base and bolster revenues by delivering advanced PV safety services and solutions. This strategic partnership stands to fuel IQVIA's growth within the life sciences sector. Simultaneously, it enables IQVIA to showcase its prowess in advanced analytics, technology solutions, and clinical research services.
Successful ventures with esteemed biotech firms like argenx serve as compelling evidence of IQVIA's excellence in these domains. Furthermore, as IQVIA joins forces with argenx to bring innovative therapies to patients with rare autoimmune diseases, it opens doors to untapped markets and therapeutic arenas. This diversification of its portfolio augments IQVIA's competitive edge and potential for sustained expansion within the dynamic life sciences industry.
According to Alistair Grenfell, President Europe, Middle East, Africa, and South Asia at IQVIA, the company is in an advantageous position to assist biotech clients like argenx due to its comprehensive range of services and technological capabilities. He expressed that the innovative solution is poised to aid argenx in the transformation and future-proofing of the current PV and safety organization. Ultimately, this support will enable argenx to expedite the delivery of medications to patients.
Zacks Rank & Stocks to Consider
IQV currently carries a Zacks Rank #4 (Sell).
The following better-ranked stocks from the Business Services sector are worth consideration:
Verisk AnalyticsVRSK beat the Zacks Consensus Estimate in three of the last four quarters and matched on one instance, with an average surprise of 9.9% The consensus mark for 2023 revenues is pegged at $2.66 billion, suggesting a decrease of 8.2% from the year-ago figure. The consensus estimate for 2023 earnings is pegged at $5.71 per share, indicating a 14% rise from the year-ago figure. VRSK currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Automatic DataADP currently has a Zacks Rank of 2. It outpaced the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 3.1%. The consensus estimate for fiscal 2023 revenues and earnings implies growth of 8.4% and 11.1%, respectively.
BroadridgeBR currently carries a Zacks Rank of 2. It surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and matched on one instance, the average surprise being 0.5%. The consensus estimate for fiscal 2024 revenues and earnings predicts growth of 9.3% and 8.8%, respectively.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report
Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report
Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report
IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report
